Effect of Whole-body Vibration on TcPO2

NCT ID: NCT03957811

Last Updated: 2019-08-26

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

UNKNOWN

Clinical Phase

PHASE3

Total Enrollment

80 participants

Study Classification

INTERVENTIONAL

Study Start Date

2017-04-04

Study Completion Date

2020-06-30

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

In order to determine the effect of whole body vibration on TcPO2 levels in patients with type 2 diabetes, 40 subjects will undertake whole body vibration exercise three times a week for 12 weeks. TcPO2 will be measured before and after the intervention. A second control group with type 2 diabetes will also have TcPO2 levels measured before and after the 12 weeks of the study.

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Objective: To determine the effect of whole body vibration exercise on levels of TcPO2 measured in the feet of patients with type 2 diabetes, in order to create recommendations for prevention of diabetic foot.

Material and Methods: controlled open clinical trial consisting in 2 arms, as follows: 1) control group under care for type 2 diabetes, and 2) intervention group, who, in addition to the standard care, will undergo an exercise program of whole body vibration three times a week, with progressive intensity, for a period of 12 weeks. Partial pressure of transcutaneous oxygen (TcPO2) will be measured in the feet of the participants at baseline and after 12 weeks, with 40 patients per group.

Statistical analysis: demographic information of the subjects will be described as arithmetic means, standard deviation, percentages, frequencies. Comparison between groups will be done with Student t for independent data or Mann-Whitney U when convenient. Baseline and final measurements will be compared. inter and intra group comparisons will be made by repeated measurements. For qualitative values, chi square will be used. Multivariate analysis will be performed to control for confounding variables. The level of significance will be a value of 0.05.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Diabetes Mellitus, Type 2

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

PARALLEL

There will be two parallel groups. One will receive the standard treatment for diabetes, and the other will receive standard treatment plus sessions of vibration exercise therapy.
Primary Study Purpose

TREATMENT

Blinding Strategy

NONE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Controls

Subjects under treatment for diabetes will receive the standard treatment for their condition.

Group Type NO_INTERVENTION

No interventions assigned to this group

Intervention

Subjects under treatment for diabetes not diagnosed for diabetic foot will receive the standard treatment plus exercise on a vibrator platform for a period of 12 weeks.

Group Type EXPERIMENTAL

Whole body Vibration exercise

Intervention Type OTHER

Intervention will consist of sessions of exercise on a whole body vibration platform, three times a week for 12 weeks.

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Whole body Vibration exercise

Intervention will consist of sessions of exercise on a whole body vibration platform, three times a week for 12 weeks.

Intervention Type OTHER

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Non-smokers.
* Residents of Mexico City
* Both sexes.
* 40 to 69 years old.
* Agreeing to participate through signature of informed consent.
* HbA1c between 6.0 and 9.0 %.
* Blood pressure less than or equal to130/80.
* Total cholesterol ≤ 240 mg/dL, triglycerides ≤300 mg/dL.
* Stable weight over the last 6 months ( \<10% variation).

Exclusion Criteria

* With exposed lesions in subcutaneous tissue (ulcers) in the sole of the foot, diabetic foot (Wagner 3 or more) or intermittent claudication.
* With important alterations in balance.
* With a recent surgery.
* Gravidity.
* Deep venous thrombosis.
* With pacemaker.
* Recent myocardial ischemia.
* Orthopedic implants.
* Recently-placed mammary prosthesis.
* Exoskeletal prosthesis.
* Discopathies.
* Neoplasia in the last 5 years.
* History of 2 episodes of severe hypoglycemia in the last year.
* Chronic kidney disease with creatinine clearance estimated at \<60 ml/min.
* Severe non-proliferative retinopathy, uncontrolled macular edema.
* Hepatic failure (Child-Pugh "C") and/or heart failure (functional Class - NYHA-: III-IV).
* Patients with hemoglobinopathies, severe anemia (≤7.5 g/dL), known hemolytic disease.
Minimum Eligible Age

40 Years

Maximum Eligible Age

69 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

Instituto Nacional de Ciencias Medicas y Nutricion Salvador Zubiran

OTHER

Sponsor Role collaborator

Instituto Nacional de Rehabilitacion

OTHER_GOV

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Gerardo Rodríguez Reyes

Medical Science Researcher

Responsibility Role PRINCIPAL_INVESTIGATOR

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

Instituto Nacional de Rehabilitacion

Mexico City, Mexico City, Mexico

Site Status RECRUITING

Countries

Review the countries where the study has at least one active or historical site.

Mexico

Central Contacts

Reach out to these primary contacts for questions about participation or study logistics.

Gerardo Rodríguez Reyes, MS

Role: CONTACT

+525559991000 ext. 13221

Facility Contacts

Find local site contact details for specific facilities participating in the trial.

Gerardo Rodriguez Reyes, MS

Role: primary

5559991000 ext. 13221

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

2234

Identifier Type: OTHER

Identifier Source: secondary_id

2416

Identifier Type: -

Identifier Source: org_study_id

More Related Trials

Additional clinical trials that may be relevant based on similarity analysis.

Self-Managed Walking Improves Function
NCT00611988 COMPLETED PHASE2